Mali Ketzinel Gilad

Title: Mali Ketzinel Gilad: Innovator in Mucosal Immunization

Introduction

Mali Ketzinel Gilad, based in Jerusalem, Israel, is an accomplished inventor known for his significant contribution to the field of immunization. With one patent to his name, Gilad's groundbreaking work focuses on a novel method for administering the hepatitis A virus (HAV) vaccine through rectal administration.

Latest Patents

Gilad's patent addresses the challenges associated with traditional vaccine administration methods that rely on injections. His innovative approach, titled "Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine," proposes a method that facilitates absorption through mucosal tissue, specifically the rectum. This technique allows the HAV vaccine to be successfully administered in forms such as suppositories, providing a user-friendly alternative to invasive needle-based injections.

Career Highlights

Mali Ketzinel Gilad is associated with Hadasit Medical Research Services and Development Ltd., where he applies his expertise to advance medical research. His work not only enhances vaccination strategies but also seeks to improve patient compliance and reduce procedural hardships typically associated with injections.

Collaborations

Throughout his career, Gilad has collaborated with notable coworkers, including Evelyn Zeira and Hilla Giladi. These partnerships highlight the collaborative nature of scientific research, contributing to the development and enhancement of immunization techniques.

Conclusion

Mali Ketzinel Gilad's contributions to the field of immunization, particularly through his innovative patent on rectal administration of the HAV vaccine, exemplify the potential for new methodologies in healthcare. His work stands as a testament to the power of creativity and collaboration in achieving significant advancements in medical research and patient care.